Ivermectin as adjuvant to hydroxychloroquine in patients resistant to standard treatment for SARS-CoV-2: results of an open-label randomized clinical study
Kishoria et al., Paripex - Indian Journal of Research, doi:10.36106/paripex/4801859
https://c19ivm.org/kishoria.html